Lipid Therapeutics’ LT-02 is a specially formulated phospholipid that augments the natural protective layer of the colon. With this treatment approach, Lipid Therapeutics is pursuing the first programme worldwide that targets the treatment of pathological alterations in the colon barrier function of colitis patients, which are thought to be one of the main causes of the disease. This compelling treatment concept, which has already been successfully tested in clinical trials, holds great promise for an effective alternative in the treatment of this disease.

Lipid Therapeutics and Dr. Falk Pharma will jointly develop LT-02 in a clinical phase IIb trial. After the successful completion of the study, Dr. Falk Pharma will have the right to perform pivotal studies as a basis for obtaining marketing authorisation in Europe. In exchange, Lipid Therapeutics will receive milestone payments as well as royalties on net sales.

”One of our major company objectives is the development of new therapies for patients suffering from inflammatory intestinal diseases. Lipid Therapeutics’ LT-02 fits very well in our portfolio and we are convinced that it will fulfil the requirements of a safe and effective drug for the treatment of ulcerative colitis with an exceptionally high level of acceptance by physicians and patients alike,” said Ursula Falk, Managing Director of Dr. Falk Pharma GmbH.

"We are proud of the progress that we have made with our lead product and its novel mechanism of action. We are also rather pleased to enter into this agreement with Dr. Falk Pharma in order to complete further development and commercialisation of the product,” said Dr. Gerhard Keilhauer, CEO of Lipid Therapeutics. “We are delighted to partner with Dr. Falk Pharma, a leading European specialist in the field of chronic inflammatory diseases of the digestive tract, along with its high commitment to delivering novel and effective therapies to patients.”